BENGALURU (Reuters) – Granules India reported a 7.8% rise in fourth-quarter profit, spurred by strong growth in its business of making active pharmaceutical ingredient (API) for drugs.
The company’s consolidated net profit rose to 1.20 billion rupees ($14.7 million) in the quarter ended March 31, from 1.11 billion rupees a year earlier.
Granules’s consolidated revenue from operations rose 16% to 11.96 billion rupees, but a 17% jump in its total expenses ate into the profit growth.
The company’s revenue from finished dosages, its largest division, rose 16% year-on-year, but that was easily outpaced by its API segment, its second-biggest, where revenue jumped 48%.
Granules reported a 38% jump in sales of paracetamol, which is both an API and a ready-for-consumption drug it sells only in the European Union.
However, the company’s biggest market is the United States, from where it gets 31%. The drugs it sells in the country includes skeletal muscle relaxant methocarbamol, whose sales surged 60% in the quarter.
Last month, Glenmark Life Sciences Ltd posted a 48% rise in quarterly profit, driven by growth in its mainstay API business.
Granules’s shares were down 1.6% after the results. ($1 = 81.7800 Indian rupees)
(Reporting by Kashish Tandon; Editing by Sonia Cheema)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.